Acumen Pharmaceuticals press release (ABOS): Q1 GAAP EPS of -$0.33 beats by $0.03. – Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027Â
Acumen Pharmaceuticals GAAP EPS of -$0.33 Beats by $0.03
Acumen Pharmaceuticals press release (ABOS): Q1 GAAP EPS of -$0.33 beats by $0.03. - Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027Â